<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; CT</title>
	<atom:link href="http://www.tapanray.in/tag/ct/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Clinical Trials: Critical Need To Improve Patient Participation With Informed Consent</title>
		<link>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent</link>
		<comments>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/#comments</comments>
		<pubDate>Mon, 18 Apr 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[consent]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[II]]></category>
		<category><![CDATA[III]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[informed]]></category>
		<category><![CDATA[IV]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[naive]]></category>
		<category><![CDATA[participation]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[phase I]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7600</guid>
		<description><![CDATA[On April 13, 2016, an article in the Wall Street Journal (WSJ) titled, “Clinical Trials Need More Subjects” underscored an important point that the rate at which the clinical researchers are able to recruit and retain patients for ‘Clinical Trials &#8230; <a href="http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Credibility Erosion of Pharma Accelerating?</title>
		<link>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-credibility-erosion-of-pharma-accelerating</link>
		<comments>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/#comments</comments>
		<pubDate>Mon, 10 Mar 2014 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerating]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[credibility]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USV]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5060</guid>
		<description><![CDATA[‘Big Pharma’ now seems to be desperately trying to gain the long lost high moral ground by pushing  hard its gigantic image makeover juggernaut, maintaining a strong pitch on the relevance of stringent Intellectual Property Rights (IPR) in the lives &#8230; <a href="http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make Global Pharma Responsible in Homeland for Objectionable Conduct in Clinical Trials Elsewhere”</title>
		<link>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere</link>
		<comments>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/#comments</comments>
		<pubDate>Wed, 12 Feb 2014 01:30:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Azad]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Desiraju]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[Ghulam]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[keshav]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Nabi]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[objectionable]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4988</guid>
		<description><![CDATA[In the context of his recent meeting with Commissioner Margaret A. Hamburg of US-FDA, the Drug Controller General of India (DCGI) reportedly expressed his concern to ‘The Economic Times’ on the ‘objectionable conduct’ of global pharma in new drug trials &#8230; <a href="http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Clinical Trial Regime Deserves Support, Sans Threats</title>
		<link>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-clinical-trial-regime-deserves-support-sans-threats</link>
		<comments>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/#comments</comments>
		<pubDate>Thu, 30 Jan 2014 11:19:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[catalytic]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[threats]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4943</guid>
		<description><![CDATA[Recent Supreme Court intervention compelling the Union Government to enforce stringent regulations both for approval and conduct of Clinical Trials (CT) in India, has unfortunately met with some strong resistance with stronger words. Some of these voices are from credible &#8230; <a href="http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-clinical-trial-regime-deserves-support-sans-threats/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NDDS as New Drug: Good for Patients, Great for Pharma</title>
		<link>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ndds-as-new-drug-good-for-patients-great-for-pharma</link>
		<comments>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/#comments</comments>
		<pubDate>Mon, 13 Jan 2014 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CR]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[IND]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[NDA]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rDNA]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4839</guid>
		<description><![CDATA[The Ministry of Health of India has reportedly decided to amend Rule 122 (E) of the Drugs and Cosmetics Rules, 1945 to categorize the New Drug Delivery Systems (NDDS), including ‘Controlled Release (CR)’ or ‘Modified Release (MR)’ formulations, whether a &#8230; <a href="http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ndds-as-new-drug-good-for-patients-great-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sets 2013, Dawns 2014: Top 7 Pharma Developments</title>
		<link>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=sets-2013-dawns-2014-top-7-pharma-developments</link>
		<comments>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/#comments</comments>
		<pubDate>Mon, 30 Dec 2013 23:20:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[back]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crystal]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Gazing]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[heralds]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Looking]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recounts]]></category>
		<category><![CDATA[revoke]]></category>
		<category><![CDATA[salient]]></category>
		<category><![CDATA[sets]]></category>
		<category><![CDATA[Seven]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4721</guid>
		<description><![CDATA[Wish You Good Health, Happiness, Success and Prosperity in 2014 In this article I shall focus on &#8216;Top 7 Pharma Developments’, both while ‘Looking Back to 2013&#8242; and also during my ‘Crystal Gazing 2014&#8242;. Looking Back to 2013: While looking &#8230; <a href="http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/sets-2013-dawns-2014-top-7-pharma-developments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Suspends New Drug Trials in India&#8230;Time to Shape Up?</title>
		<link>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up</link>
		<comments>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/#comments</comments>
		<pubDate>Mon, 14 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advisory]]></category>
		<category><![CDATA[AE]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[ceravix]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[CTs]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[deaths]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[expert]]></category>
		<category><![CDATA[exploitation]]></category>
		<category><![CDATA[gardasil]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mechanisms]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[SAE]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[SC]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[standing Committee]]></category>
		<category><![CDATA[stops]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRC]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3839</guid>
		<description><![CDATA[On September 30, 2013, with a damning stricture to the Drug Regulator, the Supreme Court, in response to a Public Interest Litigation (PIL) filed by the NGO Swasthya Adhikar Manch, stayed approvals for 162 applications for local Clinical Trials (CTs) of new &#8230; <a href="http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Transparency in Drug Trial Data: Thwarted by Lobbyists or Embroiled in Controversy?</title>
		<link>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy</link>
		<comments>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/#comments</comments>
		<pubDate>Mon, 05 Aug 2013 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[Arguments]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[controversy]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[embroiled]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hardcore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[Jikei]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mobilizing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[poignant]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[thwarted]]></category>
		<category><![CDATA[thwarting]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[University]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3274</guid>
		<description><![CDATA[Based on a leaked letter from overseas pharma industry bodies, a leading international daily in late July 2013 reported: “Big pharma mobilizing patients in battle over drugs trials data.” Some experts consider it as a poignant, if not a bizarre &#8230; <a href="http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond &#8216;The Magic Moment&#8217; of New Drug Marketing Approval</title>
		<link>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-magic-moment-of-new-drug-marketing-approval</link>
		<comments>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/#comments</comments>
		<pubDate>Mon, 24 Jun 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adaptive]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[AL]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredient]]></category>
		<category><![CDATA[Jangle]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhaseIV]]></category>
		<category><![CDATA[pst]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[reimbursement]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[surveillance]]></category>
		<category><![CDATA[Tacfidera]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncontrolled]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2394</guid>
		<description><![CDATA[“Uncontrolled clinical trials are causing havoc to human life. There are so many legal and ethical issues involved with clinical trials and the government has not done anything so far.” This is exactly what the Supreme Court of India observed &#8230; <a href="http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-magic-moment-of-new-drug-marketing-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
